You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (58)

Journals (0)

1-10 of 58 results for ALK–tyrosine kinase inhibitors

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

Free access

Review article

First published 2016-5

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

Ourania Romanidou, Lorenza Landi, Federico Cappuzzo [...]

Therapeutic Advances in Medical Oncology

Select article: Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR,ALK and ROS1 tyrosine kinase inhibitors: An update

Open access

Research article

First published 2024-03-19

Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR,ALK and ROS1 tyrosine kinase inhibitors: An update

Joanna Moes-Sosnowska, Adam Szpechcinski, Joanna Chorostowska-Wynimko

Tumor Biology

Select article: Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China

Open access

Research article

First published 2024

Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China

Meiling Zhang, Bei Zheng, Wenjuan Yang [...]

Clinical Medicine Insights: Oncology

Select article: Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties,efficacy,safety and place in therapy

Open access

Review article

First published 2018

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties,efficacy,safety and place in therapy

Tiziana Vavalà, Silvia Novello

Therapeutic Advances in Medical Oncology

Select article: Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database

Open access

Research article

First published 2025-10

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database

Weixing Zhao, Xiaoni Jin, Yuan Li [...]

Science Progress

Select article: Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases

Retricted access

Review article

First published 2019-4

Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases

Christan M Thomas, Chung-Shien Lee

Journal of Oncology Pharmacy Practice

Select article: Targeted therapy for NSCLC: ALK inhibition

Retricted access

Review article

First published 2012-6

Targeted therapy for NSCLC: ALK inhibition

Rachel Pearson, Jill M Kolesar

Journal of Oncology Pharmacy Practice

Select article: The potential for crizotinib in non-small cell lung cancer: a perspective review

Free access

Review article

First published 2011-11

The potential for crizotinib in non-small cell lung cancer: a perspective review

Yung-Jue Bang

Therapeutic Advances in Medical Oncology

Select article: Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Open access

Review article

First published 2024-4

Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Ugo Testa, Germana Castelli, Elvira Pelosi

Tumori Journal

Select article: Outcome of Crizotinib Treatment in a Young Woman with Heavily Pretreated ROS1-positive Lung Cancer

Retricted access

Case report

First published 2015-5

Outcome of Crizotinib Treatment in a Young Woman with Heavily Pretreated ROS1-positive Lung Cancer

Paolo Petreni, Francesca Mazzoni, Giulia Meoni [...]

Tumori Journal

1
2
3
•••
6
10 / page

Article type

Publication date

Subjects

Access